Improving Management of Patients at High Risk for Osteoporotic Fractures

This study has been completed.

Sponsor:

Information provided by:

Merck

ClinicalTrials.gov Identifier:

NCT00139438

First received: August 29, 2005

Last updated: October 25, 2009

Last verified: October 2009

History of Changes

Tracking Information

First Received Date ^ICMJE

August 29, 2005

Last Updated Date

October 25, 2009

Start Date ^ICMJE

September 2004

Primary Completion Date

June 2005 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

Original Primary Outcome Measures ^ICMJE

Bone mineral density (BMD) testing rates

Change History

Complete list of historical versions of study NCT00139438 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

BMD testing, osteoporosis medication prescriptions, fracture

Original Secondary Outcome Measures ^ICMJE

Osteoporosis medication treatment rates and medication

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Improving Management of Patients at High Risk for Osteoporotic Fractures

Official Title ^ICMJE

Improving Management of Patients at High Risk for Osteoporotic Fractures

Brief Summary

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Condition ^ICMJE

Osteoporosis

Intervention ^ICMJE

Behavioral: Disease Management Assessment

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

4266

Completion Date

Not Provided

Primary Completion Date

June 2005 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.

Gender

Both

Ages

45 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT00139438

Other Study ID Numbers ^ICMJE

2005_049, 038

Has Data Monitoring Committee

Not Provided

Responsible Party

Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.

Study Sponsor ^ICMJE

Merck

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Daniel H. Solomon, M.D., M.P.H.

Brigham and Woman's Hospital

Information Provided By

Merck

Verification Date

October 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top